Compare FuelCell Energy Inc (FCEL) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FuelCell Energy Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? FuelCell Energy Inc trades at $13.86 (market cap $1.24B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 3.9× FuelCell Energy Inc's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, FuelCell Energy Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold FuelCell Energy Inc for 48 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| FCEL | TVTX | |
|---|---|---|
Market Cap | $1.24B | $4.88B |
Volume | 7,483,477 | 1,668,577 |
Sector | Industrials | Health |
52-Week High | $36.01 | $67.52 |
52-Week Low | $6.00 | $26.79 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | $818.79M | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCEL trades at $15.495, down 5.35% today, with a bearish technical signal and mixed analyst ratings. The company shows persistent losses, with a net income margin of -113.6% in 2025, though revenue grew to $158.16M. Recent news highlights a securities class action lawsuit and a brief stock rally, reflecting high volatility and investor uncertainty amid ongoing financial challenges.
The outlook remains cautious due to sustained unprofitability and legal risks, but analyst consensus targets $21.57 suggest potential upside if execution improves. Key risks include cash burn, competitive pressures, and the outcome of litigation, requiring careful risk assessment for investors considering exposure to this speculative energy stock.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
